Implications of the Doha Declaration on the Trips Agreement and Public Health - Health Economics and Drugs Series No. 012: Abbreviations and acronyms

Table of Contents

Foreword
Acknowledgements
Abbreviations and acronyms
Executive summary
Introduction
Scope
The role of TRIPS and IPRs
Public health measures
	Option 1
	Option 2
Flexibility in TRIPS
	Interpretation
	Compulsory licences
	Emergency
	Exhaustion
Members with insufficient or no manufacturing capacities
	Addressed problem
	Possible approaches
		(a) Article 31 (f)
		(b) Article 30
		(c) Moratorium
	Safeguards
	Compulsory licence in the importing country
	Economic feasibility
	Legal implementation
Transfer of technology to LDCs
Extension of transitional period for LDCs
Special treatment under TRIPS
Legal status of the Doha Declaration
Issues not covered in the Declaration
Conclusions
Annex 1 - Doha Declaration on the TRIPS Agreement and Public Health
Annex 2 - Levels of development of pharmaceutical industry, by country
References

Abbreviations and acronyms

ARIPO	African Regional Industrial Property Organization
DSU	Understanding on Rules and Procedures Governing the Settlement of Disputes
EC	European Commission
EMR	Exclusive Marketing Rights
EU	European Union
GATT	General Agreement on Tariffs and Trade
IIPI	International Intellectual Property Institute
IPRs	Intellectual property rights
LDCs	Least developed countries
MFN	Most-favoured-nation
OAPI	Organisation Africaine de la Propriété Intellectuelle
SPS	Agreement on the Application of Sanitary and Phytosanitary Measures
TBT	Agreement on Technical Barriers to Trade
TRIPS	Agreement on Trade-Related Aspects of Intellectual Property Rights
UNCTAD	United Nations Conference on Trade and Development
UNDP	United Nations Development Programme
WHO	World Health Organization
WTO	World Trade Organization